title: Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?
abstract: A sporadic association between hidradenitis suppurativa and other diseases is reported in the literature, but few authors have described the association with Crohn's disease. Adalimumab is a fully human monoclonal antibody targeted at tumor necrosis factor alpha approved for the treatment of Crohn's disease and, recently, for active moderate to severe hidradenitis suppurativa in adult patients that do not respond adequately to systemic conventional treatment. We report an unusual case of a paradoxical effect of adalimumab in the onset of hidradenitis suppurativa in a 40-year-old woman during the treatment of Crohn's disease.
authors.affiliation: Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Martina
authors.affiliation: Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Campanati
authors.affiliation: Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
authors.forename: Katia
authors.initials: K
authors.lastname: Giuliodori
authors.affiliation: Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
authors.forename: Annamaria
authors.initials: A
authors.lastname: Offidani
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D017497:Hidradenitis Suppurativa / Q000209:etiology* / Q000473:pathology* / Q000628:therapy; D006801:Humans
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab